Targeting Stem Cells in Multiple Myeloma for Improved Outcomes

Targeting Stem Cells in Multiple Myeloma for Improved Outcomes

Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of drug-resistant disease that carries a dismal prognosis. Relapse is dependent on stem cell functions. We are talking to Dr. William Matsui of Johns Hopkins University School of Medicine to get a better understanding of the drivers of these functions and how they may lead to novel therapies for relapsed disease.

Panelists

Talk Recorded on Dec. 20, 2017, 5 p.m. EST </> Embed

Hear Talk Audio




  • Edward L. Snitzer March 1, 2018, 4:40 p.m.  US/Eastern

    why don't i have sound

  • Anonymous User Dec. 20, 2017, 2:28 p.m.  US/Eastern

    Parthenolide is a natural product that is said to target MM stem cells. There was a clinical trial taking place in the UK with it some years ago but I never heard the outcome. Do you know the result of the trial?

  • Anonymous User Dec. 20, 2017, 2:20 p.m.  US/Eastern

    A research paper showed that andrographolide selectively kills multiple myeloma stem cells. However it didn't do it when it was tested in a simulated bone marrow environment. Does he know what it is in that simulated microenvironment that stops the andrographolide from working? This is the research paper: https://www.ncbi.nlm.nih.gov/pubmed/21417826

  • Anonymous User Dec. 18, 2017, 11:58 p.m.  US/Eastern

    Is there a test or a marker which can predict if myeloma will or will not relapse in a patient?

  • Anonymous User Dec. 18, 2017, 11:53 p.m.  US/Eastern

    Do myeloma stem cells have the same genetic features as mature myeloma plasma cell?